That’s not a headline you’ve read before, I’ll bet. New evidence suggests that drug companies invest too much in therapies targeting diseases at late stages, and not enough in prevention or early-state therapies.
It is emotionally satisfying and socially acceptable to say that buying an extra few months of life is priceless, but if resources invested in such drugs could have been invested in drugs that would have dramatically increased the quality or length of lives of other patients, it is not evil to suggest that the resources were misallocated.
Read the entire column at Forbes.com.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment